iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Cipla gets license from Novartis for Galvus

10 Apr 2023 , 02:56 AM

Cipla Limited has entered into a perpetual license agreement with Novartis Pharma AG of Switzerland to produce and sell Galvus and Galvus combination brands, which are used to treat type 2 diabetes.

The agreement will take effect from January 1, 2026, subject to certain conditions being met beforehand. In the meantime, the company said that it will continue to market and distribute Galvus-branded products.

Galvus is a leading brand in the Dipeptidyl Peptidase-4 (DPP4) sector and is widely recognized as one of the top brands in oral diabetic medication.

With reported sales of Rs 268 crore (IQVIA MAT February 2023), Galvus has the potential to make a substantial contribution to Cipla’s portfolio in the diabetes care continuum space.

The agreement is anticipated to strengthen Cipla’s position in the diabetes category in India, solidifying its standing as one of the leading players in this market segment.

At around 2.52 PM, Cipla is trading 0.90% higher at Rs 901.40, against the previous close of Rs 893.35 on NSE. The counter touched an intraday high and low of Rs 904.50 and Rs 894.20 respectively.

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • Cipla
  • Cipla Licensing agreement
  • Cipla news
  • Novartis Pharma
  • Pharma news
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.